IN Brief:
- The European filing concerns beta-lactoglobulin made through precision fermentation rather than extracted from milk.
- 21st.BIO uses a production platform based on Aspergillus oryzae and offers process technology to industrial partners.
- European commercialisation remains conditional on the EU safety assessment and any subsequent authorisation.
21st.BIO has filed an application under the European Union’s Novel Food framework for BLG Essential+, a beta-lactoglobulin ingredient made through precision fermentation. The Danish industrial biotechnology business is seeking authorisation for a microbial production route distinct from conventional dairy processing. The application, disclosed on 12 November, follows what 21st.BIO describes as US regulatory clearance for sales in October 2025. The EU filing neither establishes a European launch date nor permits the ingredient to be placed on the market before the applicable authorisation is obtained.
Beta-lactoglobulin is the predominant whey protein found in cow’s milk. Its amino-acid composition and functional characteristics make it useful in protein-rich food and nutrition formulations. Conventional BLG reaches ingredient manufacturers through the processing and fractionation of milk whey, so its supply is tied to dairy production volumes and the operating economics of whey processing plants. Precision fermentation offers a different production route: a microorganism is cultivated in controlled conditions to produce the target protein, which must then be separated, purified and prepared to the required food-grade specification.
The platform behind BLG Essential+ uses Aspergillus oryzae, a microorganism with a long history in food fermentation, including the production of traditional fermented foods. That heritage is relevant but cannot substitute for assessment of the specific production strain, process, finished ingredient and intended uses. 21st.BIO says its platform has been developed through work extending back to technology associated with Novonesis, and it now licenses strains and manufacturing processes to partners capable of industrial production. It also provides pilot production, technology transfer, scale-up and regulatory support.
21st.BIO licenses production strains and processing know-how to industrial partners, instead of relying exclusively on sales from its own ingredient production. Partners can adopt elements of the process within suitable fermentation operations. Moving from a validated process to reliable industrial output requires consistent fermentation performance, purification yields, microbiological control and reproducible ingredient quality. The dimensions of that investment depend on available fermentation vessels, downstream separation equipment, utilities and the specifications imposed by prospective food customers. The company has not identified a new European plant or a confirmed construction programme in this filing.
A peer-reviewed study published in 2025 examined the safety-related genetic characteristics of the A. oryzae strain lineage used in the platform. According to 21st.BIO, the work documented the absence of the known mycotoxin biosynthesis pathways assessed in the study and inactivation of a penicillin G gene cluster. Those findings form part of the company’s account of its strain-characterisation programme. They should not be read as a regulatory determination that every possible hazard has been excluded. EFSA’s evaluation will consider the submitted evidence relevant to the particular novel ingredient and its proposed uses.
Fermentation changes the origin of the ingredient but not necessarily the protein structures relevant to allergenicity. A protein that closely matches milk-derived beta-lactoglobulin may retain similar functionality and may remain relevant to milk-protein allergy even though no dairy cattle are involved in its production. Ingredient developers must consider identification, specification, segregation and labelling requirements appropriate to the authorised product. Its suitability for different foods will depend both on regulatory conditions and on performance in the finished recipe, including processing stability and sensory characteristics.
EU novel food clearance is a prerequisite for placing this fermentation-derived ingredient on the market under the conditions sought in the application. Development work may continue, but food manufacturers planning product launches need sufficient certainty about permitted uses, specifications and supply reliability before committing to a production schedule. In a market where conventional whey prices and availability can change with milk production and processing demand, a separate fermentation-based supply route could provide another sourcing option. The extent of any economic or environmental advantage remains dependent on process efficiency, energy sources, input materials and downstream recovery rather than the production method’s name alone.
21st.BIO is calling for a more predictable and accelerated approval pathway for well-characterised proteins made through established production platforms, while retaining food-safety assessment. Chief executive Thomas G. Schmidt has linked the application to European investment and the risk that companies develop manufacturing capacity in jurisdictions where routes to market are clearer. That is the company’s policy position, not a change already agreed by EU institutions. The next regulatory milestone is the safety assessment of BLG Essential+ and any subsequent Commission decision; commercial European use and prospective factory investment depend on the outcome.
